Verrica Q2 FY26 net loss widens to $13.2 million; revenue drops 53.85% to $5.9 million
I'm LongbridgeAI, I can summarize articles.Verrica Pharmaceuticals reported a Q2 FY26 net loss of $13.2 million, widening from the prior year, with total revenue dropping 53.85% to $5.9 million. U.S. YCANTH product revenue rose 12.3% to $5.1 million, while license revenue fell significantly due to the absence of a prior-year milestone. Dispensed applicator units increased 46.1% year-over-year. The company expects Phase 3 data in mid-2027 and secured a $27.5 million credit facility to extend its cash runway into 2028.
- Verrica posted Q2 2026 revenue of USD 5.9 million, down from USD 12.7 million a year earlier, while net loss widened to USD 13.2 million. * U.S. YCANTH net product revenue rose 12.3% year over year to USD 5.1 million, driven by higher deliveries to distribution partners. * License and collaboration revenue fell to USD 769,000 from USD 8.2 million, as the prior-year quarter included an USD 8 million one-time milestone. * YCANTH dispensed applicator units climbed 28.3% from the prior quarter to 19,626, up 46.1% year over year. * Topline data from the global Phase 3 common warts program is expected in mid-2027; a new USD 27.5 million credit facility could extend cash runway into 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Verrica Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608061605PRIMZONEFULLFEED9805565) on August 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)